---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002793"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:00:43.111954+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Treace Q4 revenue $33.4M (+39% YoY); FY22 guidance $125-130M (32-38% growth)

## Summary
- Full-year 2021 revenue $94.4M (+65% YoY); net loss ($20.7M) or ($0.43)/share vs. ($4.3M) in 2020.
- Q4 gross margin 81.1% (+220 bps YoY); operating expenses $32.7M from $15.4M in Q4 2020.
- Cash $105.8M at Dec 31; FY22 revenue guided $125-130M.
- ALIGN3D clinical data: 0.9% recurrence at 12 months, 0.0% at 24 months post-Lapiplasty.
- Expanded patent portfolio: 32 granted US patents, over 30 pending applications.

## SEC filing metadata
- accession: 0000950170-22-002793
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017022002793/0000950170-22-002793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017022002793/tmci-20220303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002793
- JSON: https://secwatch.observer/filing/0000950170-22-002793.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.